Matrix Stiffness-Upregulated MicroRNA-17-5p Attenuates the Intervention Effects of Metformin on HCC Invasion and Metastasis by Targeting the PTEN/PI3K/Akt Pathway
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Metformin, a traditional first-line anti-hyperglycemic agent for diabetes, recently exhibits better antitumor effect in hepatocellular carcinoma (HCC). However, its resistance and tolerance mechanism in HCC remains largely unknown. Here, we investigated whether increased matrix stiffness attenuated the intervention effects of metformin on HCC invasion and metastasis, and explored its underlying molecular mechanism. METHODS: FN-coated gel substrates with 6, 10, and 16 kPa, which simulated the stiffness of normal, fibrotic, and cirrhotic liver tissues respectively, were established to evaluate matrix stiffness-mediated effects on HCC cells. Alterations in morphology, proliferation, motility, and invasive/metastatic-associated genes (PTEN, MMP2, MMP9) of HCC cells grown on different-stiffness substrates were comparatively analyzed before and after metformin intervention. Subsequently, the underlying molecular mechanism by which higher matrix stiffness attenuates antitumor effects of metformin in HCC was further elucidated. RESULTS: Metformin significantly inhibited proliferation, migration, and invasion of HCC cells. Compared with the controls on lower-stiffness substrate, HCC cells grown on higher-stiffness substrate exhibited an obvious resistance to intervention effects of metformin on proliferation, migration, invasion and metastasis. High stiffness stimulation significantly activated the miR-17-5p/PTEN/PI3K/Akt signaling pathway in HCC cells via integrin β1 and in turn resulted in MMP2 and MMP9 upregulation. Meanwhile, integrin β1 knockdown or PI3K inhibitor partially reversed the activation of the above signaling molecules. For HCC cells grown on the same-stiffness substrate, metformin remarkably upregulated PTEN expression and suppressed the activation of the PI3K/Akt/MMP pathway, but no effect on integrin β1 expression. Importantly, the increase in fold of PTEN expression and decrease in folds of Akt phosphorylation level and MMP2 and MMP9 expressions in the treated HCC cells with metformin on 16-kPa stiffness substrate were evidently weakened compared with those in the controls on the 6-kPa stiffness substrate. CONCLUSIONS: Increased matrix stiffness significantly attenuates the inhibitory effect of metformin on HCC invasion and metastasis, and a common pathway of PTEN/PI3K/Akt/MMPs activated by mechanical stiffness signal and inactivated by metformin contributes to matrix stiffness-caused metformin resistance. To the best of our knowledge, this is the first report to clarify the mechanism of metformin intervention resistance from the perspective of tumor biophysical microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · cited 3×
“Biochemical cue-regulated drug resistance and tolerance have been well documented (6, 7, 10).”
BackgroundThe molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713 · cited 2×
“Other studies also reveal that gene KRAS mutation-mediated acquired resistance occurs in CRC (7, 8).”
BackgroundChaudhuri, O., Koshy, S. T., Branco da Cunha, C., Shin, J.-W., Verbeke, C. S., Allison, K. H., & Mooney, D. J. (2014) · Nature Materials · doi:10.1038/nmat4009 · Cited by 820 · cited 1×
“In addition to clinical evidences, some basic researches also support that increased matrix stiffness heightens malignant characteristics of cancer including proliferation, invasion, metastasis, angiogenesis, and recurrence (13, 27, 28).”
BackgroundAdaptive mutability of colorectal cancers in response to targeted therapies
Russo, M., Crisafulli, G., Sogari, A., Reilly, N. M., Arena, S., Lamba, S., Bartolini, A., Amodio, V., Magrì, A., Novara, L., et al. (2019) · Science · doi:10.1126/science.aav4474 · Cited by 433 · cited 2×
“Biochemical cue-regulated drug resistance and tolerance have been well documented (6, 7, 10).”
BackgroundDestabilization of NOXA mRNA as a common resistance mechanism to targeted therapies
Montero, J., Gstalder, C., Kim, D. J., Sadowicz, D., Miles, W., Manos, M., Cidado, J. R., Paul Secrist, J., Tron, A. E., Flaherty, K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12477-y · Cited by 80
Cited by
Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy
Jiang, Y., Zhang, H., Wang, J., Liu, Y., Luo, T., & Hua, H. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01252-0 · Cited by 491
Modulating extracellular matrix stiffness: A strategic approach to boost cancer immunotherapy
Mai, Z., Lin, Y., Lin, P., Zhao, X., & Cui, L. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-06697-4 · Cited by 398
“Elevated ECM stiffness activates the FAK/RhoA/ROCK and PI3K/AKT signaling pathways via integrins, thereby increasing the expression of MMP2 and MMP9, and enhancing the invasiveness of cancer cells [50].”
BackgroundExtracellular matrix stiffness: Mechanisms in tumor progression and therapeutic potential in cancer
Zhang, M., & Zhang, B. (2025) · Experimental Hematology & Oncology · doi:10.1186/s40164-025-00647-2 · Cited by 269
Li, M., Zhang, X., Wang, M., Wang, Y., Qian, J., Xing, X., Wang, Z., You, Y., Guo, K., Chen, J., et al. (2022) · Cancer Communications · doi:10.1002/cac2.12364 · Cited by 181
“The existing in vivo and in vitro evidence from our and other studies all supports that increased matrix stiffness strengthens the malignant characteristics of HCC cells and promotes their invasion and metastasis in different ways, including triggering epithelial-mesenchymal transition (EMT) occurrence [18, 19], facil…”
BackgroundMethodSelf-citationA synergistic regulation works in matrix stiffness-driven invadopodia formation in HCC
Zhang, X., Zhao, Y., Li, M., Wang, M., Qian, J., Wang, Z., Wang, Y., Wang, F., Guo, K., Gao, D., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2023.216597 · Cited by 35
Self-citation
Metadata
- Authors
- Gao, X., Qiao, X., Xing, X., Huang, J., Qian, J., Wang, Y., Zhang, Y., Zhang, X., Li, M., Cui, J., & Yang, Y.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2020-08-19
- Volume
- 10
- Pages
- 1563-1563
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W3069403444
- Cited by
- 59
- References
- 5
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.